STARD9

Across TCGA pan-cancer cohorts, STARD9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STARD9 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher STARD9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STARD9 expression acts as an unfavorable survival marker.

ESCA and READ are the cancer types where STARD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.187	0.711	<.001	36	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	21	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STARD9–ESCA (OS)

Open the ESCA breakdown →